CUMBERLAND PHARMACEUTICALS INC

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

CPIX$5.37+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

	2025	2024
Revenues:
Net product revenue	$40,396,278	$36,537,704
Other revenue	4,125,153	1,330,241
Net revenues	44,521,431	37,867,945
Costs and expenses:
Cost of products sold	6,667,207	6,585,972
Selling and marketing	19,098,153	17,023,023
Research and development	5,566,498	4,816,206
General and administrative	11,946,909	11,126,901
Amortization and impairment	4,034,657	4,748,252
Total costs and expenses	47,313,424	44,300,354
Operating loss	(2,791,993)	(6,432,409)
Interest income	476,748	334,444
Other income - gain on insurance proceeds	—	237,089
Interest expense	(495,990)	(605,508)
Loss before income taxes	(2,811,235)	(6,466,384)
Income tax (expense) benefit	(40,256)	22,669
Equity in loss of investee	(13,220)	—
Net loss	(2,864,711)	(6,443,715)
Net (income) loss at subsidiary attributable to noncontrolling interests	28,583	(36,055)
Net loss attributable to common shareholders	$(2,836,128)	$(6,479,770)
Loss per share attributable to common shareholders:
Basic	$(0.19)	$(0.46)
Diluted	$(0.19)	$(0.46)
Weighted-average common shares outstanding:
Basic	14,854,619	14,060,272
Diluted	14,854,619	14,060,272

See accompanying notes to consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.